Advertisement

Pharmacotherapy and External Devices for Erectile Dysfuncton

  • James K. Kuan
  • Gerald B. Brock
Chapter

Abstract

Through history societies have searched for potions, elixirs, and aphrodisiacs, hoping to find a simple, effective means to enhance male sexual performance. Until recently the role of the male sexual health specialist in this matter was limited. Since the elucidation of the NO/cGMP second messenger pathway of cavernous smooth muscle, we have learned that erectile function can be enhanced with inhibition of phosphodiesterase 5 (PDE5) enzyme activity. Sildenafil citrate was the first of such agents available under US Food and Drug Administration approval, now joined by vardenafil and tadalafil. The availability of these agents has ignited a revolution in the management of erectile dysfunction (ED), resulting in the development of drugs that target other important signaling pathways. One such agent is apomorphine, a centrally acting dopaminergic drug. Thus, the previously designated first-line modalities (intracavernous injection, intraurethral suppository, vacuum constriction device) are now considered as second-line and are reserved for those in whom oral agents fail.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Heaton JPW, Adams MA, Morales A: A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Intl Impot Res 1997, 9: 117–121.Google Scholar
  2. 2.
    Morales A, Heaton JPW: Nonsurgical treatments for erectile dysfunction: oral, topical, intracavernous, and vacuum devices. In Atlas of Clinical Urology. Edited by Vaughan ED Jr., Perlmutter AP. Philadelphia: Current Medicine, Inc.; 1999:4. 1–4. 13.Google Scholar
  3. Guiliano F, Montorsi F, Mirone V, et al Switching from intracavernous prostaglandin El injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. J Urol 2000, 164:708–711.Google Scholar
  4. 4.
    Burnett AL: Nitric oxide in the penis: physiology and pathology. J Urol 1997, 157: 320–324.Google Scholar
  5. 5.
    Carson CC, Burnett AL, Levine LA, Nehra A: The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology2002, 60 (suppl 2B ): 12–27.Google Scholar
  6. 6.
    Hellstrom WJG, Gittelman M, Karlin G, etal: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. JAndrol2002, 23: 763–771.Google Scholar
  7. Brock GB, McMahon CG, Chen KK, et al Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Uro12002, 168 (4 pt 1):1332–1336.Google Scholar
  8. Heaton JWP, Morales A, Adams M, et al Resolution of erectile failure after oral treatment with apomorphine. Urology 1995, 45:200–203.Google Scholar
  9. 9.
    WHO International Society for Impotence Research: Oral non-endocrine treatment. In Erectile Dysfunction http://www.issir.org.Google Scholar
  10. 10.
    Paoletti R: Biochemistry and pharmacology of prostaglandin El: introductory remarks. In Prostaglandin El in Atherosclerosis. Edited by Sinzinger E, Rogatti W. New York: Springer-Verlag; 1986: 3–7.CrossRefGoogle Scholar
  11. 11.
    Molderings GJ, Van Ahlen H, Gothert M: Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Intl Impot Res 1992, 4: 19.Google Scholar
  12. Kifor J, Williams GH, Vickers MA, et al Tissue angiotensin lI as a modulator of erectile function: I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997, 157:1920–1925.Google Scholar
  13. 13.
    Zhang P, Christ GJ, Brink PR: PGE1-induced alterations in Maxi-K+ channel activity in cultured human corporal smooth muscle cells. J Urol 1995, 155 (suppl 6): 78A.Google Scholar
  14. 14.
    Lue TF: Male sexual dysfunction. In Smith’s General Urology, edn 15. Edited byTanagho EA, McAninch JW. New York: McGraw-Hill/Appleton & Lange; 2001: 788–810.Google Scholar
  15. 15.
    Porst H: Vasoactive substances in erectile dysfunction: a survey of 10 years global experience. In Penile Disorders. Edited by Porst H. Berlin: Springer-Verlag; 1977: 175–196.Google Scholar
  16. Bresolle F, Costa P, Rouzier-Panis R, et al Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. EurJ Clin Pharmacol 1996, 49:411–415.Google Scholar
  17. 17.
    Porst H: The rationale for prostaglandin El in erectile failure: a survey of world-wide experience. J Urol 1996, 155: 802–815.PubMedCrossRefGoogle Scholar
  18. 18.
    Porst H, BuvatJ, Meuleman E, etal: Intracavernous alprostadil alfadex: an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Intl Impot Res 1998, 10: 225–231.CrossRefGoogle Scholar
  19. 19.
    Valdevenito R, Melman A: Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Intl Impot Res 1993, 150: 1822–1824.Google Scholar
  20. Goldstein I, Borges FD, Fitch WP, et al Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin El. J Urol 1990, 143:304A (abstract 463).Google Scholar
  21. 21.
    WHO International Society for Impotence Research: Table 9–3, Incidence of pain with trimix. In Erectile Dysfunction http://www.issir.org.Google Scholar
  22. 22.
    Stack) W, Hasun R, Marberger M: Intracavernous injection of prostaglandin El in impotent men. J Urol 1988, 140: 66.Google Scholar
  23. 23.
    Lee LM, Stevenson RWD, Szadz G: Prostaglandin El versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1989, 141: 549.PubMedGoogle Scholar
  24. 24.
    WHO International Society for Impotence Research: Table 9–4, Penile scarring with trimix. In Erectile Dysfunction http://www.issir.org.Google Scholar
  25. 25.
    Manning M, Junemann KP: Pharmacotherapy of erectile dysfunction. In Male Infertility and Sexual Dysfunction. Edited by Hellstrom WJG. New York: Springer-Verlag; 1997: 440–451.CrossRefGoogle Scholar
  26. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997, 336:1–7.Google Scholar
  27. 27.
    Lewis R: Twenty years of vacuum therapy for erectile dysfunction in the United States. In Penile Disorders. Edited by Porst H. Berlin: Springer-Verlag; 1997: 162–174.Google Scholar
  28. 28.
    Nadig PW: Vacuum erection devices: a review. World J Urol 1990, 8: 114–118.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • James K. Kuan
  • Gerald B. Brock

There are no affiliations available

Personalised recommendations